Panorama: Safety and Effectiveness of Spinal Cord Stimulation With Automatic Control to Treat Chronic Pain in an Extended Trial

Sponsor
Saluda Medical Pty Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT02161627
Collaborator
(none)
69
10
2
10
6.9
0.7

Study Details

Study Description

Brief Summary

The aims of the study are to compare automatic control of spinal cord stimulation with manual control in patients with chronic pain of the trunk and limbs

Condition or Disease Intervention/Treatment Phase
  • Device: Saluda Medical External Trial System
  • Device: Saluda Medical External Trial System
N/A

Detailed Description

Subjects will use the Saluda Medical External Trial System to compare automatic control of spinal cord stimulation with manual control in a randomized, blinded, crossover study.

Study Design

Study Type:
Interventional
Actual Enrollment :
69 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Prospective, Multicenter, Randomized Double-blind Crossover Study Examining the Safety and Effectiveness of Spinal Cord Stimulation Incorporating Feedback to Treat Patients With Chronic Pain of the Trunk and/or Limbs in an Extended Trial
Study Start Date :
Jul 1, 2014
Actual Primary Completion Date :
May 1, 2015
Actual Study Completion Date :
May 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Automatic Control

Automatic Control using Saluda Medical External Trial System

Device: Saluda Medical External Trial System

Active Comparator: Manual Control

Manual Control using Saluda Medical External Trial System

Device: Saluda Medical External Trial System

Outcome Measures

Primary Outcome Measures

  1. Percentage of Subjects With Improved Pain Relief and/or Stimulation Side Effects During the Automatic Control Arm Relative to the Manual Control Arm [20 days]

    After subjects experience both automatic and manual control after 20 days, subjects are asked to compare pain relief and stimulation side effects between the two arms of the study (blinded) in two separate domains using two 5-point Likert scales. The outcome measure for the primary objective is the percentage of subjects who report improved pain relief with no worsening of stimulation side-effects or improved stimulation side-effects with no loss of pain relief during the automatic control arm relative to the manual control arm. These subjects were considered successful for the primary outcome.

Secondary Outcome Measures

  1. Number of Adverse Events as a Measure of Safety [20 days]

  2. Compare change from baseline of pain scores between automatic and manual control stimulation [20 days]

    Pain scores are obtained from the Visual Analog Scale (VAS) administered at baseline and after each arm of the study

  3. Compare change from baseline of quality of life scores, between automatic and manual control stimulation [20 days]

    Quality of life scores are obtained from the Short Form - 36 (SF-36), and EuroQol-5D-5L questionnaires administered at baseline and after each arm of the study

  4. Compare patient satisfaction with stimulation as measured on a 5-point Likert scale between automatic and manual control stimulation [20 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Patients enrolled in this study must meet the following inclusion criteria:
  1. Have been diagnosed with chronic, intractable pain of the trunk and/or limbs (VAS ≥ 5), which has been refractory to conservative therapy for a minimum of 3 months.

  2. Have been approved to undergo a trial of SCS.

  3. Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician

  4. Be on a stable dose (no new, discontinued, or changes in dose) of all prescribed pain medication for at least 4 weeks prior to the trial

  5. Be 18 years of age or older at the time of enrollment

  6. Be willing and capable of giving informed consent

  7. Be willing and able to comply with study-related requirements, procedures, and visits

  8. Females of childbearing age must have a negative urine pregnancy test at baseline

Exclusion Criteria:
Patients enrolled in this study must not meet the following exclusion criteria:
  1. Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator

  2. Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcomes

  3. Are not a surgical candidate due to a diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus

  4. Have a diagnosis of scoliosis that precludes lead placement

  5. Have a condition, treatable with SCS, that requires leads to be inserted into the cervical region

  6. Have an existing drug pump and/or SCS system or another active implantable device such as a pacemaker

  7. Have a condition currently requiring or likely to require the use of MRI or diathermy

  8. Have pain due to a malignant disease

  9. Have a life expectancy of less than 1 year

  10. Have an active systemic or local infection

  11. Be allergic, or have shown hypersensitivity, to any materials of the neurostimulation system which come in contact with the body

  12. Be pregnant or nursing (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal)

  13. Have within 6 months of enrollment a significant untreated addiction to dependency producing medications or have been a substance abuser (including alcohol and/or illicit drugs)

  14. Be concomitantly participating in another clinical study

  15. Be involved in an injury claim under current litigation

  16. Have a pending or approved worker's compensation claim

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Pain Center of Arizona Phoenix Arizona United States 85027
2 Arizona Pain Specialists Scottsdale Arizona United States 85258
3 Center for Neurosciences Tucson Arizona United States 85718
4 Premier Pain Management Shrewsbury New Jersey United States 07702
5 University Pain Management Center Somerset New Jersey United States 08873
6 Center for Clinical Research Winston-Salem North Carolina United States 27103
7 St Luke's Hospital, Neurosurgical Associates Bethlehem Pennsylvania United States 18015
8 Performance Spine & Sports Physicians East Norriton Pennsylvania United States 19403
9 Fox Chase Pain Management Feasterville-Trevose Pennsylvania United States 19053
10 Thomas Jefferson University Philadelphia Pennsylvania United States 19107

Sponsors and Collaborators

  • Saluda Medical Pty Ltd

Investigators

  • Principal Investigator: Michael J Cousins, MD DSc, Pain Management Research Institute and Kolling Institute, University of Sydney at the Royal North Shore Hospital
  • Principal Investigator: Ashwini Sharan, MD, Department of Neurosurgery, Thomas Jefferson University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Saluda Medical Pty Ltd
ClinicalTrials.gov Identifier:
NCT02161627
Other Study ID Numbers:
  • SBWSH1302
  • U1111-1157-5143
First Posted:
Jun 12, 2014
Last Update Posted:
Oct 3, 2016
Last Verified:
Sep 1, 2016
Keywords provided by Saluda Medical Pty Ltd
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 3, 2016